CClinicalTrials.gg
Not yet recruitingNCT06441383SANDMANUpdated Jun 7, 2024

Assessment of Sleep Disordersin People Living With HIV in the Era of New Antiretroviral Therapies in North of France

An observational study in HIV Infections and Sleep Disorder, sponsored by Tourcoing Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-07.

Sponsored by Tourcoing Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,100
Ages
18 Years and older
Sex
All
01

Study summary

People living with HIV (PLHIV) appear to present with sleep-related complaints more frequently than the general population, with a prevalence of 50-70%. The latest French multi-center epidemiological data are dated. The prevalence of the different types of sleep disorders, however, is poorly documented, with the literature focusing mainly on insomnia and neuropsychological disorders that can lead to sleep disorder-like symptoms, and on the impact of antiretroviral drugs in particular. However, there are other sleep disorders such as sleep apnea syndrome (SAHOS) or restless legs syndrome. SAHOS has been studied in small series of patients.

This multicenter, cross-sectional study will identify and update the functional complaints presented by PLHIV, estimate the prevalence of people at high risk of sleep apnea syndrome, and study the associated socio-demographic factors, in relation to HIV infection and antiretrovirals. This study could open up avenues for new management approaches and earlier detection of sleep disorders.

02

Conditions studied

  • HIV Infections
  • Sleep Disorder

Browse trials for

03

In context

Sleep Wake Disorders

788 studies on the registry are indexed under Sleep Wake Disorders; 186 are open to participants now.

This study's planned enrollment of 1,100 is above the median of 114 across 215 observational studies indexed under Sleep Wake Disorders.

Browse Sleep Wake Disorders studies →

Lead sponsor

Tourcoing Hospital is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The target population is all adults living with HIV. The study will be offered to all PLHIV at the time of their annual specialist consultation with their infectiologist in the referring hospital centers in northern France.

Inclusion criteria

  • PLHIV usually treated at referral centers in northern France.

Exclusion criteria

Exclusion Criteria:

  • Minor patient;
  • Patient with insufficient understanding of the French language, as judged by the investigator;
  • Patient unable to give free and informed consent;
  • Refusal to participate;
  • Patient under legal protection, guardianship or curatorship;
  • Pregnant and breast-feeding women.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,100 participants (estimated)
Patient registry
No

Interventions

  • OtherPittsburgh Sleep Quality Index

    The the Pittsburg Sleep Quality Index (PSQI) questionnaire is a standardized tool for the subjective assessment of sleep. Sleep is described according to 7 components: subjective sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disorders, medication use and daytime dysfunction. The sum of the scores for these 7 components gives an overall score of 21 points maximum. The presence of sleep disorders will be defined according to the results of the PSQI, with a value above 5 defining the presence of sleep disorders.

06

What researchers measure

Primary outcomes

  1. Prevalence of sleep disorders

    The presence of sleep disorders will be defined according to the results of the Pittsburg Sleep Quality Index (PSQI), with a value greater than 5 defining the presence of sleep disorders.

    Time frame: at baseline

Secondary outcomes

  1. Prevalence of Obstructive Sleep Apnea-Hypopnea Syndrome

    The Berlin score defines the signs suggestive of Obstructive Sleep Apnea-Hypopnea Syndrome. A score ≥ 2 positive categories will define a high risk of Obstructive Sleep Apnea-Hypopnea Syndrome

    Time frame: at baseline

  2. Prevalence of Restless Legs Syndrome

    The International Restless Legs Syndrome (RLS) Severity Scale will identify patients with symptoms in favor of RLS.

    Time frame: at baseline

07

Study locations

1 site
  • CH Tourcoing
    Tourcoing, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441383
Lead sponsor
Tourcoing Hospital
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jul 1, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jun 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion